About
Eupraxia Pharmaceuticals Inc (TO:EPRX) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 17 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Mar 13 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Feb 20 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Feb 20 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Feb 19 2026
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants